在多发性硬化症中延长纳他珠单抗间隔给药的医疗资源利用和成本。

IF 2.3 Q3 CLINICAL NEUROLOGY Neurodegenerative disease management Pub Date : 2022-06-01 DOI:10.2217/nmt-2021-0038
Marcello Moccia, Ilaria Loperto, Laura Santoni, Silvia Masera, Giuseppina Affinito, Antonio Carotenuto, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino
{"title":"在多发性硬化症中延长纳他珠单抗间隔给药的医疗资源利用和成本。","authors":"Marcello Moccia,&nbsp;Ilaria Loperto,&nbsp;Laura Santoni,&nbsp;Silvia Masera,&nbsp;Giuseppina Affinito,&nbsp;Antonio Carotenuto,&nbsp;Roberta Lanzillo,&nbsp;Maria Triassi,&nbsp;Vincenzo Brescia Morra,&nbsp;Raffaele Palladino","doi":"10.2217/nmt-2021-0038","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aims:</b> Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. <b>Methods:</b> In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. <b>Results:</b> Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. <b>Conclusion:</b> Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.</p>","PeriodicalId":19114,"journal":{"name":"Neurodegenerative disease management","volume":"12 3","pages":"109-116"},"PeriodicalIF":2.3000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.\",\"authors\":\"Marcello Moccia,&nbsp;Ilaria Loperto,&nbsp;Laura Santoni,&nbsp;Silvia Masera,&nbsp;Giuseppina Affinito,&nbsp;Antonio Carotenuto,&nbsp;Roberta Lanzillo,&nbsp;Maria Triassi,&nbsp;Vincenzo Brescia Morra,&nbsp;Raffaele Palladino\",\"doi\":\"10.2217/nmt-2021-0038\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aims:</b> Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. <b>Methods:</b> In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. <b>Results:</b> Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. <b>Conclusion:</b> Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.</p>\",\"PeriodicalId\":19114,\"journal\":{\"name\":\"Neurodegenerative disease management\",\"volume\":\"12 3\",\"pages\":\"109-116\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurodegenerative disease management\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2217/nmt-2021-0038\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurodegenerative disease management","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2217/nmt-2021-0038","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 4

摘要

目的:Natalizumab被批准为每4周输注一次(标准间隔剂量[SID])治疗复发-缓解型多发性硬化症(MS)。与SID相比,延长间隔给药(EID)可降低进行性多灶性白质脑病(PML)的风险,但对医疗资源和成本的影响尚不清楚。方法:在这项基于人群的研究中,我们纳入了208名接受那他单抗治疗的MS患者,这些患者被分为EID(过去18个月内≤15次输注;n = 51;年龄= 33.7±11.1岁;女性= 72.5%)和SID(18个月内>15次输注);n = 157;年龄= 36.5±10.8岁;女性= 68.1%)组。结果:Natalizumab EID减少MS门诊就诊(p = 0.01)和相关费用(p = 0.03),降低Natalizumab成本(p)。结论:Natalizumab EID与降低直接治疗费用相关,显然没有额外的医疗负担。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis.

Aims: Natalizumab is approved as an infusion every 4 weeks (standard-interval dosing [SID]) in relapsing-remitting multiple sclerosis (MS). Extended-interval dosing (EID) reduces risk of progressive multifocal leukoencephalopathy (PML) compared with SID, but the impact on healthcare resources and costs remains unknown. Methods: In this population-based study, we included 208 natalizumab-treated MS patients who were classified into EID (≤15 infusions in the previous 18 months; n = 51; age = 33.7 ± 11.1 years; female = 72.5%) and SID (>15 infusions in the previous 18 months; n = 157; age = 36.5 ± 10.8 years; female = 68.1%) groups. Results: Natalizumab EID had fewer MS outpatient visits (p = 0.01) and related costs (p = 0.03), and lower natalizumab costs (p < 0.01) compared with SID, without changes in other healthcare resources and costs. Conclusion: Natalizumab EID is associated with reduced direct treatment costs, apparently without additional healthcare burden.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.30
自引率
0.00%
发文量
35
期刊最新文献
Investigation of nonmotor symptoms and their clinical correlates in patients with Parkinson's disease. Detailed investigation of the levodopa response rates in distinct motor subscores in Parkinson's disease patients with and without STN-DBS. Correction. Economic evaluation of mHealth solutions in PD: where do we stand? Advances in the management of Alzheimer's disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1